Esperion Therapeutics Stock Price. Everything You Need To Know About The Esperion Therapeutics Stock!
Esperion Therapeutics, Inc. is a pharmaceutical company headquartered in Vero Beach, Florida, that went public on 2013-06-24. The company currently employs 199 full-time employees and is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C).
Esperion Therapeutics’ bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines that aim to help patients with atherosclerotic cardiovascular disease (ASCVD), or heterozygous familial hypercholesterolemia (HeFH). The firm’s products include NEXLETOL, NEXLIZET, NILEMDO, and NUSTENDI.
NEXLETOL is an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. NEXLIZET and NUSTENDI contain bempedoic acid and ezetimibe and lower elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
Staying up-to-date with the latest developments in the stock market can be crucial to making informed investment decisions. While researching stocks share price today, premarket trends, and market cap can provide valuable insights to investors, it is important to conduct thorough research and due diligence before making any investment decisions. By staying informed and keeping up with the latest developments in the pharmaceutical industry, investors can make informed decisions and stay ahead of the curve in the dynamic world of finance.
Esperion Therapeutics Stock Price. Everything You Need To Know About The Esperion Therapeutics Stock! performance
- Employees 199
- Company HQ Vero Beach
- Website https://www.esperion.com/
- ESPR Asset Type Common Stock
- ESPR Market Capitalization 403.4M
- Earnings Per Share -2.03
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0
Are you a retail investor from Malaysia, Thailand, Indonesia, or Vietnam looking to invest in the US stock market? Look no further than Esperion Therapeutics. As a Content Marketing expert at Zorion, we have analyzed this stock and have investment insights and recommendations specifically tailored to help you make informed decisions. Esperion Therapeutics is an innovative biopharmaceutical company focused on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol levels. With our investment resources and educational materials, you can further expand your investment knowledge and confidently invest in Esperion Therapeutics. Start your investment journey today and benefit from the potential growth and profitability of this promising stock.
